You are here: Industry Insights > COVID-19

News List

Potential cytokine storm treatment identified for severe COVID-19 patients europeanpharmaceuticalreview
June 09, 2020
Treating COVID-19 patients with respiratory distress with acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor reduced inflammation and improved their breathing within three days.
AbbVie and partners to develop monoclonal antibody against Covid-19 pharmaceutical-technology
June 09, 2020
AbbVie has partnered with Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) to develop a monoclonal antibody therapeutic for the prevention and treatment of Covid-19.
Oxford Biomedica partners VMIC for vaccine manufacturing pharmaceutical-technology
June 09, 2020
UK-based gene and cell therapy group Oxford Biomedica has partnered with non-profit Vaccines Manufacturing and Innovation Centre (VMIC) for the manufacturing of viral vector-based vaccines.
EMA to assess conditional authorisation of first COVID-19 treatment in European Union expresspharma
June 09, 2020
The assessment of the benefits and risks of remdesivir is being performed under a reduced timeline and an opinion could be issued within weeks, depending on the robustness of the data submitted.
Study finds COVID-19 convalescent plasma therapy safe, with 76% patients improving worldpharmanews
June 08, 2020
The country's first convalescent plasma transfusion trial results have been peer-reviewed and published, showing 19 out of 25 patients improving with the treatment and 11 discharged from the hospital.
Study identifies potential approach to treat patients with severe COVID-19 worldpharmanews
June 08, 2020
Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein provided clinical benefit to a small group of patients with severe COVID-19.
Hydroxychloroquine fails as postexposure prophylaxis for COVID-19 pharmatimes
June 08, 2020
Researchers have found that giving hydroxychloroquine as postexposure prophylaxis for COVID-19 did not prevent illness.
The Lancet retracts study linking hydroxychloroquine with deaths pharmatimes
June 08, 2020
The Lancet has issued a statement that a study which indicated that hydroxychloroquine was linked with higher rates of death in COVID-19 patients has been retracted, after three of its authors said they were unable to 'vouch for the veracity of the primar
CV patients finding it harder to get treatment during pandemic pharmatimes
June 08, 2020
The British Heart Foundation (BHF) is warning that patients with heart and circulatory conditions are having difficulty in getting treatment during the pandemic.
Octapharma USA extends funding for Covid-19 study following positive preliminary research data pharmaceutical-business-review
June 08, 2020
?Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic ...